Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for prostate cancer.

Lawrence Fong1, Eric J Small

  • 1University of California, San Francisco, San Francisco, CA 94143-0511, USA. Lawrence.fong@ucsf.edu

Current Oncology Reports
|April 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025
Same author

A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025
Same author

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Nature genetics·2025
Same author

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

JNCI cancer spectrum·2025
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
Same journal

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

Current oncology reports·2026
See all related articles

Novel immunotherapies targeting prostate cancer antigens show promise. These approaches, including tumor vaccines, are expanding treatment options beyond traditional androgen deprivation and chemotherapy, generating both immune and clinical responses in patients.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Advanced prostate cancer treatment relies on androgen deprivation and chemotherapy.
  • Immunotherapy offers a novel therapeutic avenue by targeting prostate cancer antigens.
  • Key immunologic targets include prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen.

Purpose of the Study:

  • To explore novel immunotherapeutic approaches for advanced prostate cancer.
  • To highlight the role of identified prostate cancer antigens as targets for immunotherapy.
  • To discuss the potential of immunotherapy to improve clinical outcomes.

Main Methods:

  • Identification of antigens expressed by prostate tissue and prostate cancer.
  • Development of immunotherapeutic strategies, including tumor vaccines.

Related Experiment Videos

  • Analysis of emerging clinical trial data on immunotherapy efficacy.

    • Main Results:

    • Immunotherapy can elicit significant immune responses in patients.
    • Emerging trials indicate that immunotherapy can also lead to clinical responses.
    • Innovations in cancer genomics and proteomics are aiding target identification.

    Conclusions:

    • Immunotherapy represents a promising expansion of advanced prostate cancer treatment options.
    • Targeting specific prostate cancer antigens can generate effective immune and clinical responses.
    • Future research will focus on optimizing and capitalizing on these immunotherapy findings.